Document is current
Any future updates will be listed below
-
Authors
Yi, Fei https://orcid.org/0009-0005-9031-2116
Cohen, Tal
Zimmerman, Natalie
Dündar, Friederike https://orcid.org/0000-0002-2301-112X
Zumbo, Paul
Eltilib, Razan
Brophy, Erica J.
Arkin, Hannah
Feucht, Judith
Gormally, Michael V.
Hackett, Christopher S.
Kropp, Korbinian N.
Etxeberria, Inaki https://orcid.org/0000-0003-2713-0836
Chandran, Smita S.
Zhao, Zeguo
Cai, Winson
Daniyan, Anthony F.
Park, Jae H. https://orcid.org/0000-0002-2903-5130
Lareau, Caleb A. https://orcid.org/0000-0003-4179-4807
Hsu, Katharine C.
Sadelain, Michel https://orcid.org/0000-0002-9031-8025
Betel, Doron https://orcid.org/0000-0002-8006-7752
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA286507, R01 CA269733, P50 CA217694, P30 CA008748, R00 HG012579, U01 AT012984)
Damon Runyon Cancer Research Foundation (CI-96-18)
Melanoma Research Foundation
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 2 June 2025
First Online: 22 July 2025
Competing interests
: C.A.K. and F.Y. are inventors on patents (PCT/US2021/0214415, ‘Immunoresponsive cells expressing dominant negative FAS and uses thereof’ and PCT/US2023/005877, ‘Novel dominant negative FAS polypeptides, cells comprising thereof and uses thereof’) related to this work. J.F. and M.S. are inventors on a patent (PCT/ US18/68134, ‘Enhanced chimeric antigen receptors and uses thereof’) related to this work which has been licensed to Atara Biotherapeutics, Fate Therapeutics, Takeda Pharmaceuticals, Mnemo Therapeutics and Minerva Biotechnologies. C.A.K. is a scientific co-founder and holds equity in Affini-T Therapeutics. C.A.K. has previously consulted for, or is on the scientific and/or clinical advisory boards of, Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, BMS, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech, Royalty Pharma, Stereo Biotherapeutics and T-knife. S.S.C. is a scientific advisor and equity holder in Affini-T Therapeutics. A.F.D. is the chief scientific officer of Promicell Therapeutics and holds equity in the company. A.F.D. is listed as an inventor on multiple patents related to CAR-T cell therapy and may be eligible to receive a portion of royalties paid to MSK by Caribou Biosciences, Tigen Pharma SA, Promicell Therapeutics and other entities that have optioned or licensed these technologies from MSK. C.A.L. is a scientific co-founder and holds equity in Cartography Biosciences. J.H.P. received consulting fees from Adaptive Biotechnologies, Affyimmune Therapeutics, Amgen, Autolus, Ascentage, Be Biopharma, Beigene, Bright Pharmaceutical Services, Caribou Biosciences, Curocell, Galapagos, In8Bio, Iovance, Jazz Pharmaceuticals, Kite, Medpace, Pfizer, Servier, Sobi, Synthekine and Takeda; received honoraria from OncLive, Physician Education Resource and MJH Life Sciences; serves on scientific advisory board of Allogene Therapeutics, Artiva Biotherapeutics and Green Cross Biopharma; and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier and Takeda. M.S. reports grants from Atara Biotherapeutics, Fate Therapeutics, Mnemo Therapeutics and Takeda outside the submitted work. Additionally, M.S. has patents issued and licensed to Juno Therapeutics, Atara Biotherapeutics, Fate Therapeutics, Takeda Pharmaceuticals and Alaya Bio. The remaining authors declare no competing interests.
